Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma
Objective. To explore the clinical efficacy and safety of apatinib combined with paclitaxel in the first-line treatment of locally advanced nasopharyngeal carcinoma. Methods. From March 2016 to June 2018, 114 patients with locally advanced nasopharyngeal carcinoma who received first-line treatment i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Emergency Medicine International |
| Online Access: | http://dx.doi.org/10.1155/2022/6293816 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554767545532416 |
|---|---|
| author | Dechao Zhan Zihong Chen Donghong Yang Jiyu Wen Wanwan Liu |
| author_facet | Dechao Zhan Zihong Chen Donghong Yang Jiyu Wen Wanwan Liu |
| author_sort | Dechao Zhan |
| collection | DOAJ |
| description | Objective. To explore the clinical efficacy and safety of apatinib combined with paclitaxel in the first-line treatment of locally advanced nasopharyngeal carcinoma. Methods. From March 2016 to June 2018, 114 patients with locally advanced nasopharyngeal carcinoma who received first-line treatment in our hospital were selected as the patient group, and those who received apatinib combined with paclitaxel concurrent radiotherapy and chemotherapy were selected as the research group (n = 54), while those who received paclitaxel concurrent radiotherapy and chemotherapy were selected as the control group (n = 60). Sixty healthy individuals in our hospital were recruited in the same period as the healthy group. The clinical effective rate, adverse reactions, 2-year overall survival rate (OS), 2-year progression-free survival rate (PFS), and quality of life were compared between the two groups, and the expression of miR-655 in the serum of each group was tested by RT-qPCR. Results. The total clinical effective rate of the research group was higher than that of the control group, and the 2-year OS and PFS of the research group were also higher than those of the control group (P<0.05). Both groups of patients could tolerate the treatment, but the incidence of hypertension and proteinuria in the research group was higher than that in the control group (P<0.05). The expression of miR-655 in the serum of patients was lower than that of the healthy group (P<0.05). After treatment, miR-655 in serum increased in both the groups and miR-655 in the research group was higher than that in the control group (P<0.05). The 2-year survival rate of OS and PFS in patients with low expression of miR-655 was significantly lower than that in patients with high expression of miR-655 (P<0.05). Conclusion. Apatinib combined with paclitaxel concurrent radiotherapy and chemotherapy is effective and well-tolerated in the treatment of locally advanced nasopharyngeal carcinoma, which improves the quality of life of patients and can be popularized in clinical practice. In addition, the increase of miR-655 may be a target for treating nasopharyngeal carcinoma. |
| format | Article |
| id | doaj-art-cfba5c5388ac422590cbff24a5546026 |
| institution | Kabale University |
| issn | 2090-2859 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Emergency Medicine International |
| spelling | doaj-art-cfba5c5388ac422590cbff24a55460262025-02-03T05:50:38ZengWileyEmergency Medicine International2090-28592022-01-01202210.1155/2022/6293816Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal CarcinomaDechao Zhan0Zihong Chen1Donghong Yang2Jiyu Wen3Wanwan Liu4Cancer CenterCancer CenterCancer CenterCancer CenterCancer CenterObjective. To explore the clinical efficacy and safety of apatinib combined with paclitaxel in the first-line treatment of locally advanced nasopharyngeal carcinoma. Methods. From March 2016 to June 2018, 114 patients with locally advanced nasopharyngeal carcinoma who received first-line treatment in our hospital were selected as the patient group, and those who received apatinib combined with paclitaxel concurrent radiotherapy and chemotherapy were selected as the research group (n = 54), while those who received paclitaxel concurrent radiotherapy and chemotherapy were selected as the control group (n = 60). Sixty healthy individuals in our hospital were recruited in the same period as the healthy group. The clinical effective rate, adverse reactions, 2-year overall survival rate (OS), 2-year progression-free survival rate (PFS), and quality of life were compared between the two groups, and the expression of miR-655 in the serum of each group was tested by RT-qPCR. Results. The total clinical effective rate of the research group was higher than that of the control group, and the 2-year OS and PFS of the research group were also higher than those of the control group (P<0.05). Both groups of patients could tolerate the treatment, but the incidence of hypertension and proteinuria in the research group was higher than that in the control group (P<0.05). The expression of miR-655 in the serum of patients was lower than that of the healthy group (P<0.05). After treatment, miR-655 in serum increased in both the groups and miR-655 in the research group was higher than that in the control group (P<0.05). The 2-year survival rate of OS and PFS in patients with low expression of miR-655 was significantly lower than that in patients with high expression of miR-655 (P<0.05). Conclusion. Apatinib combined with paclitaxel concurrent radiotherapy and chemotherapy is effective and well-tolerated in the treatment of locally advanced nasopharyngeal carcinoma, which improves the quality of life of patients and can be popularized in clinical practice. In addition, the increase of miR-655 may be a target for treating nasopharyngeal carcinoma.http://dx.doi.org/10.1155/2022/6293816 |
| spellingShingle | Dechao Zhan Zihong Chen Donghong Yang Jiyu Wen Wanwan Liu Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma Emergency Medicine International |
| title | Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma |
| title_full | Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma |
| title_fullStr | Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma |
| title_full_unstemmed | Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma |
| title_short | Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma |
| title_sort | clinical effect of apatinib mesylate tablets combined with paclitaxel concurrent radiotherapy and chemotherapy in the first line treatment of locally advanced nasopharyngeal carcinoma |
| url | http://dx.doi.org/10.1155/2022/6293816 |
| work_keys_str_mv | AT dechaozhan clinicaleffectofapatinibmesylatetabletscombinedwithpaclitaxelconcurrentradiotherapyandchemotherapyinthefirstlinetreatmentoflocallyadvancednasopharyngealcarcinoma AT zihongchen clinicaleffectofapatinibmesylatetabletscombinedwithpaclitaxelconcurrentradiotherapyandchemotherapyinthefirstlinetreatmentoflocallyadvancednasopharyngealcarcinoma AT donghongyang clinicaleffectofapatinibmesylatetabletscombinedwithpaclitaxelconcurrentradiotherapyandchemotherapyinthefirstlinetreatmentoflocallyadvancednasopharyngealcarcinoma AT jiyuwen clinicaleffectofapatinibmesylatetabletscombinedwithpaclitaxelconcurrentradiotherapyandchemotherapyinthefirstlinetreatmentoflocallyadvancednasopharyngealcarcinoma AT wanwanliu clinicaleffectofapatinibmesylatetabletscombinedwithpaclitaxelconcurrentradiotherapyandchemotherapyinthefirstlinetreatmentoflocallyadvancednasopharyngealcarcinoma |